Xevinapant plus avelumab in advanced solid tumours, with a dose expansion in advanced non-small-cell lung cancer: exploratory biomarker, safety and efficacy analyses from an open-label, nonrandomised phase Ib study

Background: Xevinapant, an inhibitor of apoptosis protein (IAP) inhibitor, has shown promising activity in combination with anticancer agents, including radiotherapy, and, in preclinical studies, anti-PD-(L)1 antibodies. This, in part, is due to its ability to restore apoptosis and increase antitumo...

詳細記述

書誌詳細

主要な著者:	Glenwood Goss, Tudor Ciuleanu, Rodryg Ramlau, Daniel J. Renouf, Quincy Chu, Ewa Kalinka, Piotr Sawrycki, Jonathan Bramson, Brad H. Nelson, Rafael Crabbé, Eric LaCasse, Bryan Lo, Daniela A. Sahlender, Philippa Crompton, Franck Brichory, Luke Piggott, Michael Schenker, Rosalyn Juergens
フォーマット:	Artigo
言語:	Inglês
出版事項:	SAGE Publishing 2025-05-01
シリーズ:	Therapeutic Advances in Medical Oncology
オンライン･アクセス:	https://doi.org/10.1177/17588359251332154
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!